CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER IN CLASSIC HODGKIN LYMPHOMA
Valeria Spina(Ente Ospedaliero Cantonale), Davide Rossi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Jan Maciej Zaucha(Gdańsk Medical University), Micol Giulia Cittone(Institute of Oncology Research), Lodovico Terzi di Bergamo(Institute of Oncology Research), Georg Stüssi(Institute of Oncology Research), Adalgisa Condoluci(Ente Ospedaliero Cantonale), Marcello Rodari(Humanitas University), Luca Ceriani(St Thomas' Hospital), Maria Cristina Pirosa(Institute of Oncology Research), Eugenio Borsatti(Centro di Riferimento Oncologico), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pietro Bulian(Centro di Riferimento Oncologico), Michał Kurlapski(University Clinical Centre), Antonio Pinto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alessandra Stasia(Institute of Oncology Research), Martina Di Trani(Humanitas University), Deborah Piffaretti(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Carmelo Carlo‐Stella(Humanitas University), Stéphane Chauvie(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Anastasios Stathis(Princess Margaret Cancer Centre), Franco Cavalli(Institute of Social and Preventive Medicine), Katia Pini(Institute of Oncology Research), Ilaria Zangrilli(Agostino Gemelli University Polyclinic), B. Gerber(University of Zurich), Grzegorz Romanowicz(Gdańsk Medical University), S. Hohaus(Agostino Gemelli University Polyclinic), Gabriela Forestieri(Institute of Oncology Research), Ricardo Koch(Institute of Oncology Research), Valter Gattei(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alden A. Moccia(BC Cancer Agency), Martin Faderl(Institute of Oncology Research), Emanuele Zucca(Università della Svizzera italiana), Alessio Bruscaggin(Institute of Oncology Research), G. Sacchetti(Azienda Ospedaliera Ospedale Maggiore), Salvatore Annunziata(Agostino Gemelli University Polyclinic)
Cited by 0
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718